Vanguard Global Advisers
VTVT icon

Vanguard Global Advisers’s vTv Therapeutics VTVT Stock Holding History

Vanguard Global Advisers’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48K Hold
1,275
– – ﹤0.01% 3081
2026
Q1 		$50.6K Buy
+1,275
New +$46.3K ﹤0.01% 3018

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's VTVT Position: Q2 2026 in Review

Vanguard Global Advisers held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 1,275 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #3081.

Vanguard Global Advisers first reported a position in VTVT in Q1 2026 and has held it in 2 quarters since. The position peaked at $50.6K in Q1 2026. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Vanguard Global Advisers held 1,275 shares of vTv Therapeutics worth $48K as of Q2 2026.
  • Vanguard Global Advisers left its vTv Therapeutics share count unchanged in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3081 holding.
  • Vanguard Global Advisers first reported a position in vTv Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's vTv Therapeutics position peaked at $50.6K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.